I

Ionis Pharmaceuticals
D

IONS

32.310
USD
-0.37
(-1.12%)
مغلق
حجم التداول
47,036
الربح لكل سهم
-4
العائد الربحي
-
P/E
-11
حجم السوق
5,136,151,783
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    B
    BMRN
    -0.525
    (-0.76%)
    68.215 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SRPT
    -2.010
    (-1.86%)
    106.280 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار المقالات

العنوان: Ionis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.